New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 15, 2012
23:38 EDTHPY, PETM, LMT, AMGN, HD, JCP, CSCOJim Cramer's "Mad Money"
Cramer said it's downright infuriating, just when the housing market was beginning to recover, autos were getting stronger, retail sales were growing and banks looked like they were finally finding their footing, Congress has been able to undo it all and send our markets sharply lower. We're now facing the first congressionally mandated bear market we've ever seen, said Cramer, all because 536 people couldn't agree. For the year, U.S. stocks are now up just half of their counterparts in Europe, and Europe is in a recession. Cramer came up with three indicators to help investors figure out whether the effects of the fiscal cliff are baked into the markets and whether its time to begin buying back in. First: "Washington on TV" indicator. Anytime the president or member of Congress gets on the air, expect the markets to go lower. Second: Lockheed Martin (LMT), the defense contractor with a 5% dividend yield. If the U.S. falls over the fiscal cliff, Lockheed will get hurt by both defense spending cuts and a rise in dividend taxes, Cramer noted, making this stock uniquely positioned to feel the blow. Third: Investors can use Cisco (CSCO), Home Depot (HD) and Petsmart (PETM) as gauges for Washington's damage. Cramer said all three of these companies posted stellar earnings, so if they can't hold onto their gains, no one can. SELL BLOCK: Cramer reminded viewers some stocks go down because they deserve to, and that's certainly the case with J.C. Penney (JCP). The company remains a value trap and is showing no signs of improving. Penney has had three disappointing quarters in a row, Cramer noted, and sales still continue to decline, dramatically so, and the company's balance sheet is weakening. Then, continuing with his "Upside Surprise Party" series of stocks to buy as the markets continue to fall on fiscal cliff worries, Cramer recommended drug maker Amgen (AMGN). The company has a huge pipeline of new drugs on the way and a 1.7% yield. Trading at just 12x earnings with a 10.5% long-term growth rate, Cramer said he's never seen Amgen trade as low as it is right now. EXECUTIVE DECISION: Cramer sat down with Robert Carr, chairman and CEO of Heartland Payment Systems (HPY), our nation's fifth-largest payment processor. Heartland's most recent quarterly results included a 5c earnings beat on better-than-expected revenue with upside guidance. Cramer continued his recommendation and said Heartland Payment Systems is a great story. NO HUDDLE OFFENSE: Cramer offered his quick "Top 5" reasons why they shouldn't be sellers in Friday's market. First: stocks are already very oversold -- there will be a better time to sell later. Second: while many stocks will be impacted by the fiscal cliff, others, like international names, will not, which is why it's prudent to buy, not sell, into weakness. Third: everything gets baked into stock prices eventually, and stocks often bottom before big events occur, not after. Fourth: the higher taxes and spending cuts of the fiscal cliff won't be the end of the world for certain sectors, like health care and those that offer consumers a bargain. And, Fifth: companies with big dividends will likely be able to raise those dividends to cover, at least partially, any higher tax rates from the fiscal cliff. Reference Link
News For LMT;CSCO;HD;PETM;JCP;AMGN;HPY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
April 24, 2015
08:37 EDTHPYHeartland Payment shares should be bought on weakness, says SunTrust
Subscribe for More Information
06:26 EDTCSCOCisco upgraded to Conviction Buy from Buy at Goldman
Goldman added Cisco to the Conviction Buy List and maintained its $34 price target. The firm sees upside to FY16 estimates from emerging product cycles in enterprise WLAN and campus switching driven by adoption of 802.11ac Wave 2.
April 23, 2015
09:03 EDTHPYHeartland announces collaboration with PAX for EMV terminals for merchants
Subscribe for More Information
April 22, 2015
15:19 EDTAMGNAmgen management to meet with Piper Jaffray
Group luncheon to be held in Boston on April 27 hosted by Piper Jaffray.
09:22 EDTAMGNOn The Fly: Pre-market Movers
UP AFTER EARNINGS: CalAmp (CAMP), up 12.7%... Angie's List (ANGI), up 17.4%... Broadcom (BRCM), up 6.3%... Owens Corning (OC), up 3.8%... Yum! Brands (YUM), up 3.3%... Dolby Laboratories (DLB), up 3.6%... Infinera (INFN), up 2.4%... AutoNation (AN), up 2.5%... Amgen (AMGN), up 3.1%... Coca-Cola (KO), up 2%. ALSO HIGHER: Procera Networks (PKT) up 10.4% after being acquired by Francisco Partners in deal valued at $240M... Organovo (ONVO), up 19.2% after entering into a collaboration agreement with Merck Sharp and Dohme... Vical (VICL), up 5.8% after being awarded $4M contract to manufacture HIV vaccines for clinical evaluation... CTI BioPharma (CTIC), up 4.9% after announcing that Phase 3 pacritinib data will be highlighted in a late-breaking oral presentation at ASCO meeting. DOWN AFTER EARNINGS: Chipotle Mexican Grill (CMG), down 5.2%... iRobot (IRBT), down 3.6%... Cree (CREE), down 3.5%... United Rentals (URI), down 4%... Super Micro Computer (SMC), down 2.3%... Thermo Fisher (TMO), down 2.6%. ALSO LOWER: Natural Resource Partners (NRP), down 14% after reducing quarterly distribution 75% to 9c per unit... Trinity Industries (TRN), down 3.5% following a Bloomberg report that the Justice Department has initiated a criminal investigation into Trinity guardrails.
07:59 EDTAMGNAmgen price target raised to $189 from $164 at Cowen
Subscribe for More Information
07:29 EDTAMGNAmgen estimates and price target raised at UBS
Subscribe for More Information
06:03 EDTAMGNAmgen price target raised to $192 from $187 at Piper Jaffray
Subscribe for More Information
April 21, 2015
19:06 EDTAMGNOn The Fly: After Hours Movers
Subscribe for More Information
17:07 EDTAMGNAmgen shares higher by 2.69% after Q1 results, guidance
16:04 EDTAMGNAmgen raises FY15 EPS view to $9.35-$9.65 from $9.05-$9.40, consensus $9.32
Narrows FY15 revenue view to $20.9B-$21.3B from $20.8B-$21.3B, consensus $20.98B.
16:02 EDTAMGNAmgen reports Q1 EPS $2.48, consensus $2.10
Reports Q1 revenue $5.03B, consensus $4.91B.
15:28 EDTAMGNNotable companies reporting after market close
Subscribe for More Information
13:51 EDTAMGNEarnings Watch: Amgen's Enbrel, Neulasta sales key for Q1 results
Amgen (AMGN) is scheduled to report first quarter earnings after the market close on Tuesday, April 21 with a conference call scheduled for 5:00 pm ET. Amgen, a biotechnology medicines company, engages in the discovery, development, manufacture, and marketing of human therapeutic products in the areas of supportive cancer care, inflammation, nephrology, and bone diseases. EXPECTATIONS: Analysts are looking for earnings per share of $2.10 on revenue of $4.91B, according to First Call. The consensus range for EPS is $1.91-$2.25 on revenue of $4.62B-$5.13B. LAST QUARTER: Amgen reported fourth quarter EPS of $2.16 against estimates of $2.05 on revenue of $5.33B against estimates of $5.2B. With its Q4 report, Amgen also reiterated its fiscal year EPS view of 9.05-$9.40, on revenue of of $20.8B-$21.3B. Total product sales increased 8% for Q4 versus Q4 of 2013. The increase was driven primarily by Enbrel, Neulasta, Prolia, XGEVA and Vectibix .Growth for the quarter was due primarily to higher unit demand, and to a lesser extent, price. Product sales increased 6% for the full year driven by strong performance across the portfolio. STREET RESEARCH: On March 23, Piper Jaffray said the "positive" trial data Teva (TEVA) reported for its anti-CGRP antibody in migraines is another important validation for the class of drugs that is also being worked on by Amgen, Eli Lilly (LLY), and Alder Biopharmaceuticals (ALDR). The firm said it thinks Amgen is one of the leaders in CGRP antibody space and reiterated its Overweight rating and $187 price target on Amgen shares. On March 16, RBC Capital said it believes that data presented by Amgen on its evolocumab drug for hyperlipidemia.was "very positive." The firm expects the drug to be approved in late summer. It predicts that revenue from the drug will ramp modestly and steadily, and then accelerate after positive studies of the drug's effects are released in 2017. RBC Capital estimates that worldwide revenue from the drug will peak at $2.5B+. It keeps an Outperform rating on Amgen. PRICE ACTION: Amgen shares are higher by around 6% since its last earnings report on January 27, and are up 1.25% to to $168.06 in afternoon trading ahead of Tuesday's earnings report.
10:20 EDTCSCOWells thinks carrier equipment vendors factored in weak capex
Subscribe for More Information
10:01 EDTHDOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: Agios Pharmaceuticals (AGIO) initiated with a Perform at Oppenheimer... Bed Bath & Beyond (BBBY) initiated with a Buy at Cantor... BioCryst (BCRX) initiated with an Outperform at FBR... Bovie Medical (BVX) initiated with an Outperform at JMP Securities... Calavo Growers (CVGW) initiated with a Buy at Janney Capital... Clorox (CLX) initiated with a Sector Weight at KeyBanc... Coach (COH) initiated with a Sell, $32 target at Cantor... Compugen (CGEN) initiated with an Outperform at Oppenheimer... Corcept Therapeutics (CORT) initiated with an Outperform at FBR Capital... Criteo (CRTO) initiated with an Outperform at Raymond James... CytRx (CYTR) initiated with an Outperform at FBR Capital... Dollar Tree (DLTR) initiated with a Buy at Cantor... Facebook (FB) initiated with a Buy at Cleveland Research... Gap (GPS) initiated with a Hold at Cantor... Genocea (GNCA) initiated with an Outperform at FBR Capital... Geron (GERN) initiated with an Outperform at Oppenheimer... Home Depot (HD) initiated with a Hold at Cantor... HubSpot (HUBS) initiated with a Buy at Needham... Jernigan Capital (JCAP) initiated with a Buy at Wunderlich... La Jolla (LJPC) initiated with an Outperform, $43 target at Oppenheimer... Lowe's (LOW) initiated with a Hold at Cantor... Lumber Liquidators (LL) initiated with a Buy, $45 target at Cantor... New Residential (NRZ) reinstated with an Outperform at Credit Suisse... Rent-A-Center (RCII) initiated with a Buy at Cantor... Ross Stores (ROST) initiated with a Hold at Cantor... Rubicon Project (RUBI) initiated with an Outperform at Raymond James... SolarCity (SCTY) initiated with an Outperform at Northland... SolarEdge (SEDG) initiated with a Buy at Canaccord... Spectrum Brands (SPB) initiated with an Overweight at KeyBanc... Summit Materials (SUM) initiated with a Buy at BB&T... Synergy Resources (SYRG) initiated with a Buy at KLR Group... Synta Pharmaceuticals (SNTA) initiated with an Outperform at FBR Capital... TJX (TJX) initiated with a Hold at Cantor... Tiffany (TIF) initiated with a Hold at Cantor... TubeMogul (TUBE) initiated with a Market Perform at Raymond James... Urban Outfitters (URBN) initiated with a Buy at Cantor... WhiteWave Foods (WWAV) initiated with a Neutral at Janney Capital... Williams-Sonoma (WSM) initiated with a Hold at Cantor... Zafgen (ZFGN) initiated with an Outperform at FBR Capital.
08:23 EDTCSCOCisco results likely to beat expectations, says Bernstein
Bernstein expects Cisco to report stronger than expected results, due to strength in enterprise and commercial and continued momentum in switching, Bernstein believes that risks caused by service provider revenue was eliminated by the company's Q1 guidance, while currency fluctuations should not impact its near-term results. The firm keeps a $34 price target and Outperform rating on the shares.
07:29 EDTLMTLockheed Martin reports Q1 Aeronautics sales $3.13B
Subscribe for More Information
07:28 EDTLMTLockheed Martin raises FY15 EPS to $10.85-$11.15 from $10.80-$11.10
FY15 EPS consensus of $11.14. Backs FY15 revenue $43.5B-$45B, consensus $44.65B. Backs FY15 orders $43.5B-$45B. Raises FY15 consolidated operating profit to $5.35B-$5.5B from $5.3B-$5.45B. Raises FY15 business segment operating profit to $5.15B-$5.3B from $5.1B-$5.25B.
07:26 EDTLMTLockheed Martin reports Q1 EPS $2.74, consensus $2.50
Subscribe for More Information
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use